{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:11:49Z","timestamp":1786662709629,"version":"build-2736575974"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive Toxicology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.reprotox.2016.04.027","type":"journal-article","created":{"date-parts":[[2016,5,2]],"date-time":"2016-05-02T13:17:13Z","timestamp":1462195033000},"page":"87-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States"],"prefix":"10.1016","volume":"62","author":[{"given":"Marlena S.","family":"Fejzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimber W.","family":"MacGibbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Mullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reprotox.2016.04.027_bib0005","doi-asserted-by":"crossref","first-page":"51.e1","DOI":"10.1016\/j.ajog.2011.02.029","article-title":"Medication use during pregnancy, with particular focus on prescription drugs 1976\u20132008","volume":"205","author":"Mitchell","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"9 (February)","key":"10.1016\/j.reprotox.2016.04.027_bib0010","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1056\/NEJMoa1211035","article-title":"Ondansetron in pregnancy and risk of adverse fetal outcomes","volume":"368","author":"Pasternak","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"December","key":"10.1016\/j.reprotox.2016.04.027_bib0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.reprotox.2014.10.017","article-title":"Use of ondansetron during pregnancy and congenital malformations in the infant","volume":"50","author":"Danielsson","year":"2014","journal-title":"Reprod. Toxicol."},{"issue":"1 (January)","key":"10.1016\/j.reprotox.2016.04.027_bib0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/bdra.22865","article-title":"National birth defects prevention study. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects","volume":"94","author":"Anderka","year":"2012","journal-title":"Birth Defects Res. A Clin. Mol. Teratol."},{"key":"10.1016\/j.reprotox.2016.04.027_bib0025","unstructured":"(http:\/\/www.cdc.gov\/ncbddd\/heartdefects\/data.html) (accessed 11.9.2015)."},{"issue":"1 (September)","key":"10.1016\/j.reprotox.2016.04.027_bib0030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejogrb.2013.04.017","article-title":"Antihistamines and other prognostic factors for adverse outcome in hyperemesis gravidarum","volume":"170","author":"Fejzo","year":"2013","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"4 (October)","key":"10.1016\/j.reprotox.2016.04.027_bib0035","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/AOG.0000000000000479","article-title":"Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial","volume":"124","author":"Oliveira","year":"2014","journal-title":"Obstet. Gynecol."}],"container-title":["Reproductive Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623816300910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623816300910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:41:35Z","timestamp":1760190095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890623816300910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":7,"alternative-id":["S0890623816300910"],"URL":"https:\/\/doi.org\/10.1016\/j.reprotox.2016.04.027","relation":{},"ISSN":["0890-6238"],"issn-type":[{"value":"0890-6238","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States","name":"articletitle","label":"Article Title"},{"value":"Reproductive Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reprotox.2016.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}